Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 57 resultados

BICEPS: Beyond neuroInflammation new Concepts to Elucidate the immune system s vital role in Parkinson s di... Decades of research into Parkinson's disease (PD) have fallen short in fully comprehending its mechanisms, leaving us without a cure. Curren...
2024-06-25 - 2028-10-31 | Financiado

EBiSC2: EBiSC2 A sustainable European Bank for induced pluripotent Stem Cells H. LUNDBECK AS participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage EBiSC2 builds on the achievements of the European Bank for iPSCs (EBiSC1) in centralising existing capacities across Europe in a unique bank...
2019-02-28 - 2023-02-28 | Financiado

PD-MitoQUANT: PD MitoQUANT A quantitative approach towards the characterisation of mitochondrial dysfunction in... H. LUNDBECK AS participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage Mitochondrial dysfunction is implicated in Parkinson’s Disease (PD), but detailed understanding of the cause and effect in αSyn toxicity is...
2019-02-19 - 2022-07-31 | Financiado

IM2PACT: Investigating Mechanisms and Models Predictive of Accessibility of Therapeutics IM2PACT Into The B... H. LUNDBECK AS participó en un H2020: H2020-JTI-IMI2-2017-12-two-stage The overall aim is to further the understanding of the BBB in health and disease states towards the development of innovative brain delivery...
2018-12-14 - 2024-12-31 | Financiado

EHDEN: European Health Data and Evidence Network H. LUNDBECK AS participó en un H2020: H2020-JTI-IMI2-2017-12-two-stage Europe is generating huge amounts of patient-level information contained in Electronic Health Record (EHR) systems and other types of health...
2018-11-22 - 2024-10-31 | Financiado

PET-AlphaSy: PET Imaging of Alpha Synuclein Fibril Formation H. LUNDBECK AS participó en un H2020: H2020-MSCA-ITN-2018 Too often, physicians have to rely on a trial and error strategy until the most effective treatment for an individual patient is identified....
2018-08-30 - 2022-11-30 | Financiado

Syn2Psy: Synaptic Dysfunction in Neuropsychiatric Disorders H. LUNDBECK AS participó en un H2020: H2020-MSCA-ITN-2018 The large public health burden and individual suffering associated with mental disorders speaks to the need to study their biological underp...
2018-08-20 - 2023-08-31 | Financiado

PARADIGM: Patients Active in Research and Dialogues for an Improved Generation of Medicines Advancing meaning... H. LUNDBECK AS participó en un H2020: H2020-JTI-IMI2-2016-10-two-stage PARADIGM will provide a unique framework that enables structured, effective, meaningful, ethical, innovative, and sustainable patient engage...
2018-06-04 - 2020-11-30 | Financiado

IMPRiND: Inhibiting Misfolded protein PRopagation in Neurodegenerative Diseases Sofia ref. 116060 H. LUNDBECK AS participó en un H2020: H2020-JTI-IMI2-2015-07-two-stage Assemblies of tau and α-synuclein were shown to spread along interconnected neuronal networks suggesting broadly relevant therapeutic direct...
2017-04-07 - 2022-02-28 | Financiado

ROADMAP: Real world Outcomes across the AD spectrum for better care Multimodal data Access Platform Sofia... H. LUNDBECK AS participó en un H2020: H2020-JTI-IMI2-2015-06-two-stage The aim of ROADMAP is to provide the foundation for a Europe-wide real world evidence (RWE) platform in AD by piloting multi-modal data inte...
2016-12-21 - 2018-10-31 | Financiado

PHAGO: Inflammation and AD modulating microglia function focussing on TREM2 and CD33 Sofia ref. 115976 H. LUNDBECK AS participó en un H2020: H2020-JTI-IMI2-2015-05-two-stage Alzheimer’s disease (AD) is an age-related chronic neurodegenerative disease with four main pathological changes in the brain: amyloid plaqu...
2016-12-16 - 2022-04-30 | Financiado

TreatER: Clinical study in Parkinson s disease with two unique goals 1 Proof of concept of CDNF protein for... H. LUNDBECK AS participó en un H2020: H2020-SC1-2016-2017 The main focus of TreatER is conducting a randomized, placebo-controlled, first-in-human, proof-of-concept, safety and efficacy study of int...
2016-12-09 - 2020-12-31 | Financiado

SYNDEGEN: Synaptic dysfunction in Neurodegenerative Diseases H. LUNDBECK AS participó en un H2020: H2020-MSCA-ITN-2016 Neurodegenerative diseases (NDDs) of aging are a growing burden on societies. Although studies on the degeneration of neurons have been a ma...
2016-08-31 - 2021-06-30 | Financiado

EU-GliaPhD: Training Research and Raising of Public Awareness in Cell Biology and Pathology of Neuroglia H. LUNDBECK AS participó en un H2020: H2020-MSCA-ITN-2016 The research in which the young scientists of the EU-GliaPhD consortium will be trained is centred on the role of neuron-glia interactions i...
2016-08-12 - 2021-06-30 | Financiado

RADAR-CNS: Remote Assessment of Disease and Relapse in Central Nervous System Disorders H. LUNDBECK AS participó en un H2020: H2020-JTI-IMI2-2015-03-two-stage Background: Long term conditions require monitoring of patients, traditionally conducted in the clinic, to monitor treatment effects, advers...
2016-03-31 - 2022-03-31 | Financiado

PEARRL: Pharmaceutical Education And Research with Regulatory Links Innovative drug development strategies... H. LUNDBECK AS participó en un H2020: H2020-MSCA-ITN-2015 The European Pharma industry is a major contributor to EU well-being, both in public health and economic (sales >200 billion €/year) terms....
2016-02-12 - 2020-08-31 | Financiado

COSYN: Comorbidity and Synapse Biology in Clinically Overlapping Psychiatric Disorders H. LUNDBECK AS participó en un H2020: H2020-PHC-2014-2015 COSYN integrates outstanding European academic and three large Pharma to exploit genomic findings for intellectual disability (ID), autism,...
2015-12-09 - 2020-12-31 | Financiado

ADAPT-SMART: Accelerated Development of Appropriate Patient Therapies a Sustainable Multi stakeholder Approach... H. LUNDBECK AS participó en un H2020: H2020-JTI-IMI2-2015-04-two-stage-Master Progress in the life sciences and related technologies offer great potential for therapeutic benefits to patients in need. However, major ad...
2015-09-02 - 2018-04-30 | Financiado

NextGenVis: Training the Next Generation of European Visual Neuroscientists for the benefit of innovation in hea... H. LUNDBECK AS participó en un H2020: H2020-MSCA-ITN-2014 The human visual brain can learn and adapt to change, which solves many of the problems posed by an ever-changing visual environment. Howeve...
2014-12-16 - 2019-02-28 | Financiado

EPAD: European Prevention of Alzheimer’s Dementia Consortium H. LUNDBECK AS participó en un FP6: Background:The secondary prevention of Alzheimer’s dementia (AD) is achievable if we can identify individuals at risk of disease progression...
2015-01-01 - 2019-12-31 | Financiado